Solving the Complexities of T Cell Engager Development
T-cell engagers (TCEs) are a class of bispecific antibodies that simultaneously bind tumor cells and T cells, activating T cells and mediating their cytotoxic effects on tumor cells. However, their complex structure and mechanism of action demand a rigorous understanding of pharmacology, safety, and translational biology.
In this webinar, WuXi AppTec scientists discuss pharmacological approaches for TCEs, including predictive biomarker detection and the use of diverse humanized preclinical models and knock-in systems that recapitulate the immune-tumor microenvironment. Our specialists also address the bioanalytical complexities inherent to TCE therapeutics, including critical considerations in pharmacokinetic profiling and immunogenicity assessment.
Related Content
From hematologic malignancies to solid tumors Introduction: Amid a surge of advancements in immunotherapy, T cell engager (TCE) therapy has...
VIEW RESOURCEAntibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery...
VIEW RESOURCE
